Anzeige
Mehr »
Lynx Broker
Login
Montag, 21.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PJN3 ISIN: BMG070252017 Ticker-Symbol: 2QAA 
Tradegate
18.10.19
10:17 Uhr
1,760 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
AURIS MEDICAL HOLDING LTD Chart 1 Jahr
5-Tage-Chart
AURIS MEDICAL HOLDING LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,700
1,714
19.10.
1,680
1,730
18.10.

Aktuelle News zur AURIS MEDICAL Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiAuris Medical Holding - Interim AM-201 data110Auris has announced interim data from its 50-subject AM-201 Phase Ib trial for olanzapine-induced weight gain and somnolence. The drug demonstrated safety and tolerability and provided initial signals...
► Artikel lesen
11.10.Auris Medical up 2% premarket on AM-201 data3
AURIS MEDICAL Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten!
11.10.Auris Medical AG: Auris Medical Announces Positive Interim Results from AM-201 Phase 1b Study in Antipsychotic-Induced ...-
13.09.Auris Medical AG: Auris Medical Receives FDA and EMA Guidance for Keyzilen Late-Stage Clinical Development Program6
11.09.Auris Medical AG: Auris Medical Announces Notices of Allowance for U.S. and European Patent Applications Covering ...4
04.09.Auris Medical Holding Ltd. - 6-K, Report of foreign issuer2
04.09.Auris Medical AG: Auris Medical Announces Appointment of New Chief Financial Officer1
20.08.Auris Medical Holding - AM-201 proof of concept data is weeks away194Auris Medical Holding announced in July that the 50-subject AM-201 Phase Ib trial for olanzapine-induced weight gain and somnolence completed enrolment, with top-line data in five dose levels expected...
► Artikel lesen
15.08.Auris Medical AG: Auris Medical Provides Business Update and Reports First Half 2019 Financial Results3
15.08.Auris Medical reports 1H results2
15.08.Auris Medical Holding Ltd. - 6-K, Report of foreign issuer-
30.07.Auris Medical AG: Auris Medical Announces Randomization of First Patient in AM-125 Phase 2 Trial in Acute Vertigo4
19.07.Auris Medical Holding Ltd. - S-8, Securities to be offered to employees in employee benefit plans5
03.07.Auris Medical AG: Auris Medical Completes Enrollment of Phase 1b Proof-Of-Concept Trial of AM-201 in Antipsychotic-Induced ...6
04.06.Auris Medical Holding - Data coming in second half47Auris recently announced that the TRAVERS Phase II trial of AM-125 (intranasal betahistine) for treating acute vertigo is being initiated at study sites as regulatory and ethics committee approvals...
► Artikel lesen
23.05.Auris Medical AG: Auris Medical Holding Ltd Provides Corporate Update5
20.05.Auris Medical AG: Auris Medical Holding Ltd Regains Compliance with Nasdaq Minimum Bid Price Rule6
16.05.Auris Medical Holding Ltd. - 6-K, Report of foreign issuer2
15.05.Auris Medical AG: Auris Medical Announces Closing of Public Offering of Common Shares4
13.05.Auris Medical down 15% on equity offering3
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1